Clinical trial NCT01341405: Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
Official title: A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Osteoarthritis
Keywords: COX-1
COX-2
carbonic anhydrase
anti-inflammatory
Cyclooxygenase Inhibitors
Polmacoxib
Lead sponsor: CrystalGenomics, Inc.
Sponsor class: INDUSTRY
First posted: 2011-04-25
Enrollment: 125
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).

Detailed description: This is a double-blind, randomized, multicenter, noninferiority, phase 2 study. Subjects will discontinue current medications (NSAID or COX-2 inhibitor) 5-14 days prior to randomization. Paracetamol (acetaminophen; ≤2 gm/day) may be used for breakthrough pain. Other NSAIDs, COX-2 inhibitors, opioids, and corticosteroids may not be used at any time during this study. Only subjects recording average WOMAC pain score of 4 to 8 on a 0-10 numerical rating scale during the washout period and meeting all other inclusion criteria will be randomized into the study.

Male and female adults, ages 20 and older, with a history of osteoarthritis (OA) of the knee or hip diagnosed by radiograph obtained within the past 20 years and with pain at least 3 months from OA can participate in this study. OA must be confirmed by radiographs and diagnosed according to American College of Rheumatology (ACR) guidelines. Subjects must qualify as ACR global functional status I, II, or III (excluding IV) and Kellgren-Lawrence grade 1, 2 or 3 (excluding grade 4).

Subjects meeting screening criteria will be randomized to receive 28 days dosing of an active dose of CG100649 or comparator (celecoxib).

Antiarthritic efficacy will be evaluated by changes in the Western Ontario and McMaster Universities (WOMAC) OA index completed on Day 1 (Baseline) and on Days 14, 28 and 42. The WOMAC pain subscale will be evaluated at screening and on Days 1, 7, 14, 21, 28, 35 and 42.

All doses will be administered orally once daily in the morning. There are 3 planned treatment arms (2 with active compound + one comparator (celecoxib) group) with n=44 per treatment arm. Total number of subjects will be 132.

Treatment A: CG100649: 2 mg/day (Days 1-28); Treatment B: CG100649: 4 mg/day (Days 1-28); Treatment C: celecoxib: 200 mg/day (Days 1-28); Active and comparator medications will have identical appearance.

Eligibility criteria: Inclusion Criteria:

1. Males and females, age 20 years old and more, able and willing to provide written informed consent to participate in the study
2. Confirmed osteoarthritis (OA) of the knee or hip by radiograph obtained within the past 20 years and diagnosed according to American College of Rheumatology (ACR) guidelines.
3. Subject must have pain at least 3 month duration from osteoarthritis (OA)
4. Normal blood pressure (BP) \[systolic BP 90-140 mmHg, diastolic BP 50-90 mmHg\] and heart rate (HR) \[resting 45-90 beats per minute (bpm)\]
5. Subjects with hypertension should have stably taken ACE inhibitor, angiotensin II receptor (type AT1) antagonist, beta-blocker and/or diuretics at least 3 months at the time of screening in order to keep normal blood pressure. Subjects should not change or stop hypertension drug during the study.
6. Clinical Chemistry must be within 2x normal limits
7. Urinalysis must be within normal range.
8. Prior to randomization on Day 1, the mean WOMAC pain score in the index joint must be between 4 and 8 on a 0-10 numerical rating scale.
9. Subjects and their sexual partners must agree to use double barrier contraception during the study period and for 3 months afterwards or provide proof of surgical sterility or post-menopause more than 1 year.
10. Subject must be able to read and understand and follow the study instructions.

Exclusion Criteria:

1. Use of any analgesics except the study medication or paracetamol (acetaminophen) at any time during this study;
2. Use of corticosteroids or intra-articular viscosupplementation within 3 months of screening;
3. Use of antidepressants or anticonvulsants within 2 months of screening;
4. Cognitive or psychiatric disorders, or daytime use of medications (alcohol, benzodiazepines, barbiturates, muscle relaxants) that could diminish compliance with study procedures;
5. Use of anticoagulants (aspirin, warfarin, heparin) within 2 weeks of screening;
6. Use of any medications that will affect pain perception (e.g. tranquilizers, hypnotics);
7. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, or carbonic anhydrase inhibitors;
8. Use of oriental medicine (herbal medicine) or glucosamine within 14 days of dose administration
9. History of drug or alcohol abuse within one year prior to screening;
10. Known allergy or hypersensitivity to sulfa drugs;
11. History of congestive heart failure, ischemic heart disease, peripheral arterial disease, cerebrovascular disease or subjects who have one of these diseases;
12. Use of chemotherapy agents or history of cancer, other than non-metastatic skin cancer that has been completely excised, within five (5) years prior to the screening visit;
13. Subjects with gout, pseudogout, inflammatory arthritis, Paget's disease, chronic pain syndrome, fibromyalgia, or another major joint disease;
14. Subjects requiring knee or hip arthroplasty within 2 months of screening or anticipating any need for a surgical procedure on the index joint during the study;
15. Subjects who have had surgery on the affected joint within 6 months of screening and subjects with a prosthesis at the index joint;
16. History of seizure disorder;
17. Subjects with serious psychosocial co-morbidities;
18. Subjects with gastrointestinal, renal, hepatic, or coagulant disorder within 6 months of screening;
19. Esophageal or duodenal ulcer within 6 months of screening;
20. History of nasal polyps, bronchospasm, and urticaria;
21. Pregnant or breast-feeding;
22. Subject with genetic problem of galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption (because celecoxib contains lactose)

Primary outcomes:
measure: Change of the WOMAC Pain Subscale at Day 28 From Baseline
timeFrame: Baseline, Day 28
Secondary outcomes:
measure: Change of the Sum of WOMAC OA Index at Day 28 From Baseline
timeFrame: Baseline, Day 28
measure: Change of WOMAC-Stiffness Subscale at Day 28 From Baseline
timeFrame: Baseline, Day 28
measure: Change of WOMAC-Physical Function Subscale at Day 28 From Baseline
timeFrame: Baseline, Day 28
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: CrystalGenomics, Inc.
name: Sangsook Cho, Ph.D.
role: STUDY_DIRECTOR
References: